BIOPHARMA
By
Can Novartis and BioArctic’s $802M Alliance Unlock the Next Breakthrough in Neurodegenerative Drug Delivery?
Key Highlights Strategic Collaboration Targets Neurodegenerative DiseasesNovartis has entered into a research partnership with Sweden’s BioArctic, committing $30M…
Can IQVIA and Flagship Pioneering’s AI-Driven Alliance Unlock the Next $60B Wave of Breakthrough Biopharma?
Key Highlights AI-Powered Acceleration in Drug DevelopmentThe collaboration positions IQVIA’s Healthcare-grade AI® and data-driven analytics at the center…
Could Halda Therapeutics and VantAI’s $1B AI Alliance Redefine the Future of Cancer Drug Discovery?
Key Highlights Strategic Alliance to Advance Induced Proximity TherapiesHalda Therapeutics has entered into a collaboration with AI biotech…
How AbbVie Is Expanding Its Psychiatry Pipeline Through $1.2B Acquisition of Gilgamesh Pharmaceuticals’s Next-Gen Depression Drug?
Key Highlights The Promise of BretisilocinBretisilocin (GM-2505) is a novel, short-acting 5-HT2A receptor agonist and 5-HT releaser designed…
Endpoints Signal Report Finds Nearly Half of Biopharma Professionals Are Heavy AI Users, With Expectations of Major R&D Transformation Ahead
Based on Endpoints Signal Pulse Report | December 2025 A new Signal Pulse Report from Endpoints News reveals…
Chai Discovery Becomes Newest AI Unicorn Following $130 Million Series B Financing
Company valued at $1.3 billion as investors back AI-native drug discovery platform San Francisco, California Chai Discovery today…
